Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto-iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as general partner, has made an additional investment in Eurus Therapeutics Co., Ltd. (headquartered in Fujisawa City, Kanagawa Prefecture; Takato Noumi, CEO).

Overview of this investment
Eurus Therapeutics aims to develop novel genome editing technologies that do not use the CRISPR/Cas system and establish a new drug discovery platform business that can provide unprecedented therapeutic strategies.

Since the previous investment, Eurus Therapeutics has further optimized the Eurus Editor, which consists of single-stranded modified nucleic acids, to establish a safe genome editing method that allows precise editing with low risk of editing errors. The established method is not only free of nucleotide and gene selection, but has also achieved a high level of editing efficiency that is expected to be used in practical applications at the clinical level. We believe that this technology can be used to solve the problems faced by the CRISPR/Cas system.

Kyoto-iCAP has executed an additional investment of 200 million yen in recognition of the potential of Eurus Therapeutics' technology to provide a new option in the global genome editing market. The total amount raised is 810 million yen, and in addition to Kyoto-iCAP, other investors include Nissay Capital Corporation, SMBC Venture Capital Corporation, RDiscovery Corporation, Kyoto Capital Partners Corporation, Yokohama Capital Corporation, Axil Capital Partners No. 2 Limited Liability Ltd. and Sumisho Pharma International Co.

With this procurement, Eurus Therapeutics aims to begin development of its clinical pipeline and further enhance its technology.

Overview of Eurus Therapeutics, Inc.
Establishment : February 2021
Business : Development of novel gene therapies
Head Office: Fujisawa City, Kanagawa Prefecture
CEO: Takato Nohmi

About Kyoto University Innovation Capital Corporation (Kyoto iCAP)
As a wholly-owned subsidiary of Kyoto University, KYOTO-iCAP provides investment and other business support to companies that utilize research results generated by Kyoto University and other national universities. We currently operate the Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP 1 Fund") (established in January 2016) with a total value of 16 billion yen and the KYOTO-iCAP 2 Fund (established in January 2021) with a total value of 18 billion yen. The KYOTO-iCAP No. 1 Fund has a maturity of up to 20 years, and the KYOTO-iCAP No. 2 Fund has a maturity of up to 17 years, making it possible to provide long-term support for the practical application of research results from Kyoto University, which has strengths in basic research. The KYOTO-iCAP 2 Fund has a maximum maturity of 17 years. In addition, KYOTO-iCAP No. 2 Fund will invest a portion of the funds in ventures originating from national universities other than Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital Co., Ltd.
36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
TEL: 075-753-7588 FAX: 075-753-7592
E-mail: info@kyoto-unicap.co.jp